Literature DB >> 8094888

2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.

A Delannoy, G Hanique, A Ferrant.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8094888     DOI： 10.1056/NEJM199303183281116

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

Review 1.  Management of chronic lymphocytic leukaemia.

Authors:  N Kalil; B D Cheson
Journal:  Drugs Aging       Date:  2000-01       Impact factor: 3.923

2.  Phase I/II evaluation of pentostatin (2'-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia.

Authors:  S A Johnson; D Catovsky; J A Child; A C Newland; D W Milligan; R Janmohamed
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

Review 3.  Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies.

Authors:  H M Bryson; E M Sorkin
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

Review 4.  Clinical and toxicological aspects of the antineoplastic drug cladribine: a review.

Authors:  H J Guchelaar; D J Richel; M R Schaafsma
Journal:  Ann Hematol       Date:  1994-11       Impact factor: 3.673

Review 5.  Current approaches to the treatment and management of chronic lymphocytic leukaemia.

Authors:  E Montserrat; C Rozman
Journal:  Drugs       Date:  1994       Impact factor: 9.546

6.  Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL).

Authors:  Marco Montillo; Francesca Ricci; Sara Miqueleiz; Alessandra Tedeschi; Enrica Morra
Journal:  Biologics       Date:  2008-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.